2. Disease Areas
  3. Digestive System Disease
  4. Gastric Disease
  5. Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

Gastroesophageal reflux disease (GERD) is a chronic digestive disorder characterized by the abnormal backflow of stomach acid and contents into the esophagus due to lower esophageal sphincter dysfunction, leading to symptoms such as heartburn, regurgitation, chest pain, dysphagia, and a sour taste in the mouth. With a global prevalence of 10–20%, GERD is often diagnosed based on symptom response to treatment, supported by endoscopic findings or acid exposure measurements when needed. Common contributing factors include obesity, pregnancy, smoking, and certain medications. If untreated, GERD may result in complications such as esophagitis, esophageal stricture, and Barrett’s esophagus, a precancerous condition. Management involves lifestyle modifications, pharmacological therapies like antacids and proton pump inhibitors, and, in select cases, surgical intervention. Early diagnosis and appropriate treatment are crucial to prevent long-term esophageal damage and improve quality of life.

Gastroesophageal Reflux Disease (2):

Cat. No. 상품명 CAS No. Purity 화학구조
  • HY-139557A
    Zastaprazan citrate 2936619-43-9 99.86%
    Zastaprazan (JP-1366) citrate is a Proton pump inhibitor and potent potassium-competitive acid blocker. Zastaprazan citrate can be used in the research of gastrointestinal inflammatory diseases or gastric acid-related diseases such as gastroesophageal reflux disease.
    Zastaprazan citrate
  • HY-182513
    ONO-8539 459842-29-6
    ONO-8539 is an orally active prostanoid EP1 receptor antagonist with competitive, insurmountable binding and slow receptor dissociation for long-duration inhibition. ONO-8539 modulates afferent nerve function related to bladder activity, inhibits detrusor overactivity-related contractions, decreases nonvoiding contractions and voiding duration, and increases uroflow rate with ATP (HY-B2176)-induced detrusor overactivity. ONO-8539 attenuates acid-induced heartburn symptoms, extends time to first heartburn sensation, and prevents primary hypersensitivity after distal esophageal acidification. ONO-8539 can be used for the research of overactive bladder and gastroesophageal reflux disease.
    ONO-8539